Researchers have uncovered how a key Parkinson’s protein shifts between inactive and active forms, revealing the structural changes that enable certain mutations to push the protein into an overactive state.
Earlier use of a targeted radionuclide therapy delays metastatic prostate cancer progression when administered as part of a trio of drugs, according to a phase 3 clinical trial.
The protein makes blood vessels leakier to allow metastatic tumors to form in the lungs, according to a study led by investigators at Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center.
Announced Aug. 5 at Cornell Tech, a research partnership will help neighborhoods in Brooklyn, Queens and the Bronx identify where new trees are needed most to improve public health.
A protein that can dial down oxidative stress in cells helps some cancers resist treatment with a widely used class of drugs called BTK inhibitors, according to a study led by investigators at Weill Cornell Medicine.
Weill Cornell Medicine has received a three-year, $2.5 million grant from the Department of Defense to develop therapies with fewer side effects for triple-negative breast cancer, one of the most aggressive and difficult-to-treat breast cancers.
